{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:48:14Z","timestamp":1775872094914,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04333-y","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:58:05Z","timestamp":1775869085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia"],"prefix":"10.1007","volume":"75","author":[{"given":"Marina","family":"Konopleva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Mantzaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Gundabolu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolie","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rao","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Drewniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"4333_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA et al (2023) Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21:503\u2013513. https:\/\/doi.org\/10.6004\/jnccn.2023.0025","journal-title":"J Natl Compr Canc Netw"},{"key":"4333_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071419","author":"C Antier","year":"2024","unstructured":"Antier C et al (2024) Late relapse after allogeneic stem cell transplantation in patients treated for acute myeloid leukemia: relapse incidence, characteristics, role of conditioning regimen, and outcome. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16071419","journal-title":"Cancers (Basel)"},{"key":"4333_CR3","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/bmt.2017.182","volume":"52","author":"D Modi","year":"2017","unstructured":"Modi D et al (2017) Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. Bone Marrow Transplant 52:1530\u20131536. https:\/\/doi.org\/10.1038\/bmt.2017.182","journal-title":"Bone Marrow Transplant"},{"key":"4333_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA (2008) Human natural killer cells. Blood 112:461\u2013469. https:\/\/doi.org\/10.1182\/blood-2007-09-077438","journal-title":"Blood"},{"key":"4333_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.coviro.2011.10.017","volume":"1","author":"SM Vidal","year":"2011","unstructured":"Vidal SM, Khakoo SI, Biron CA (2011) Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience. Curr Opin Virol 1:497\u2013512. https:\/\/doi.org\/10.1016\/j.coviro.2011.10.017","journal-title":"Curr Opin Virol"},{"key":"4333_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000325265","volume":"3","author":"YT Bryceson","year":"2011","unstructured":"Bryceson YT et al (2011) Molecular mechanisms of natural killer cell activation. J Innate Immun 3:216\u2013226. https:\/\/doi.org\/10.1159\/000325265","journal-title":"J Innate Immun"},{"key":"4333_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3389\/fimmu.2013.00390","volume":"4","author":"R Galandrini","year":"2013","unstructured":"Galandrini R, Capuano C, Santoni A (2013) Activation of lymphocyte cytolytic machinery: where are we? Front Immunol 4:390. https:\/\/doi.org\/10.3389\/fimmu.2013.00390","journal-title":"Front Immunol"},{"key":"4333_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00281-018-0685-x","volume":"40","author":"S Guia","year":"2018","unstructured":"Guia S et al (2018) Activating and inhibitory receptors expressed on innate lymphoid cells. Semin Immunopathol 40:331\u2013341. https:\/\/doi.org\/10.1007\/s00281-018-0685-x","journal-title":"Semin Immunopathol"},{"key":"4333_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/imm.12921","volume":"154","author":"S Kumar","year":"2018","unstructured":"Kumar S (2018) Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology 154:383\u2013393. https:\/\/doi.org\/10.1111\/imm.12921","journal-title":"Immunology"},{"key":"4333_CR10","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.4049\/jimmunol.0901226","volume":"183","author":"M Carlsten","year":"2009","unstructured":"Carlsten M et al (2009) Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 183:4921\u20134930. https:\/\/doi.org\/10.4049\/jimmunol.0901226","journal-title":"J Immunol"},{"key":"4333_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","volume":"109","author":"C Fauriat","year":"2007","unstructured":"Fauriat C et al (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109:323\u2013330. https:\/\/doi.org\/10.1182\/blood-2005-08-027979","journal-title":"Blood"},{"key":"4333_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells13171464","author":"V Im\u0161irovi\u0107","year":"2024","unstructured":"Im\u0161irovi\u0107 V et al (2024) Maintaining the balance: regulation of NK cell activity. Cells. https:\/\/doi.org\/10.3390\/cells13171464","journal-title":"Cells"},{"key":"4333_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clim.2016.02.003","volume":"177","author":"L Baggio","year":"2017","unstructured":"Baggio L et al (2017) Natural killer cell adoptive immunotherapy: coming of age. Clin Immunol 177:3\u201311. https:\/\/doi.org\/10.1016\/j.clim.2016.02.003","journal-title":"Clin Immunol"},{"key":"4333_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.27281","volume":"99","author":"SO Ciurea","year":"2024","unstructured":"Ciurea SO et al (2024) Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol 99:890\u2013899. https:\/\/doi.org\/10.1002\/ajh.27281","journal-title":"Am J Hematol"},{"key":"4333_CR15","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.Ccr-17-3196","volume":"24","author":"AT Bj\u00f6rklund","year":"2018","unstructured":"Bj\u00f6rklund AT et al (2018) Complete remission with reduction of high-risk clones following Haploidentical NK-Cell therapy against MDS and AML. Clin Cancer Res 24:1834\u20131844. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3196","journal-title":"Clin Cancer Res"},{"key":"4333_CR16","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","volume":"24","author":"TA Fehniger","year":"2018","unstructured":"Fehniger TA et al (2018) A phase 1 trial of CNDO-109\u2013activated natural killer cells in patients with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 24:1581\u20131589. https:\/\/doi.org\/10.1016\/j.bbmt.2018.03.019","journal-title":"Biol Blood Marrow Transplant"},{"key":"4333_CR17","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","volume":"123","author":"V Bachanova","year":"2014","unstructured":"Bachanova V et al (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123:3855\u20133863. https:\/\/doi.org\/10.1182\/blood-2013-10-532531","journal-title":"Blood"},{"key":"4333_CR18","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051\u20133057. https:\/\/doi.org\/10.1182\/blood-2004-07-2974","journal-title":"Blood"},{"key":"4333_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2217\/imt.09.47","volume":"1","author":"L Barkholt","year":"2009","unstructured":"Barkholt L et al (2009) Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 1:753\u2013764. https:\/\/doi.org\/10.2217\/imt.09.47","journal-title":"Immunotherapy"},{"key":"4333_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2217\/imt.11.174","volume":"4","author":"S Farhan","year":"2012","unstructured":"Farhan S et al (2012) NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy 4:305\u2013313. https:\/\/doi.org\/10.2217\/imt.11.174","journal-title":"Immunotherapy"},{"key":"4333_CR21","doi-asserted-by":"publisher","first-page":"e1115178","DOI":"10.1080\/2162402X.2015.1115178","volume":"5","author":"U Koehl","year":"2016","unstructured":"Koehl U et al (2016) Advances in clinical NK cell studies: donor selection, manufacturing and quality control. Oncoimmunology 5:e1115178. https:\/\/doi.org\/10.1080\/2162402X.2015.1115178","journal-title":"Oncoimmunology"},{"key":"4333_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.bbmt.2010.02.018","volume":"16","author":"DA Rizzieri","year":"2010","unstructured":"Rizzieri DA et al (2010) Natural killer cell-enriched donor lymphocyte infusions from a 3-6\/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 16:1107\u20131114. https:\/\/doi.org\/10.1016\/j.bbmt.2010.02.018","journal-title":"Biol Blood Marrow Transplant"},{"key":"4333_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","volume":"110","author":"L Ruggeri","year":"2007","unstructured":"Ruggeri L et al (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110:433\u2013440. https:\/\/doi.org\/10.1182\/blood-2006-07-038687","journal-title":"Blood"},{"key":"4333_CR24","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1182\/blood.V128.22.1161.1161","volume":"128","author":"M Thakar","year":"2016","unstructured":"Thakar M et al (2016) Prophylactic natural killer cell immunotherapy following HLA-haploidentical hematopoietic cell transplantation prevents relapse and improves survival in patients with high-risk hematological malignancies. Blood 128:1161\u20131161. https:\/\/doi.org\/10.1182\/blood.V128.22.1161.1161","journal-title":"Blood"},{"key":"4333_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3389\/fimmu.2017.00631","volume":"8","author":"JP Veluchamy","year":"2017","unstructured":"Veluchamy JP et al (2017) The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments. Front Immunol 8:631. https:\/\/doi.org\/10.3389\/fimmu.2017.00631","journal-title":"Front Immunol"},{"key":"4333_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00879","author":"S Kweon","year":"2019","unstructured":"Kweon S et al (2019) Expansion of human NK cells using K562 cells expressing OX40 ligand and short exposure to IL-21. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.00879","journal-title":"Front Immunol"},{"key":"4333_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R et al (2016) Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med 8:652","journal-title":"Sci Transl Med"},{"key":"4333_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2018.02.033","volume":"422","author":"M Vela","year":"2018","unstructured":"Vela M et al (2018) Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett 422:107\u2013117. https:\/\/doi.org\/10.1016\/j.canlet.2018.02.033","journal-title":"Cancer Lett"},{"key":"4333_CR29","unstructured":"Trikha P, O'Donnell L, Bradbury H, Ciurea SO, Kararoudi MN, et al. (2020) Deep characterization of MBIL21 ex vivo-expanded NK cells using mass cytometry, functional assays, and RNA sequencing establishes product consistency across different manufacturing sites and systems. , 25th European Hematology Association (EHA). Abstract #EP1487 (2020) 11\u201314"},{"key":"4333_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jcyt.2016.02.006","volume":"18","author":"JL Oyer","year":"2016","unstructured":"Oyer JL et al (2016) Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment. Cytotherapy 18:653\u2013663. https:\/\/doi.org\/10.1016\/j.jcyt.2016.02.006","journal-title":"Cytotherapy"},{"key":"4333_CR31","doi-asserted-by":"publisher","first-page":"e1509819","DOI":"10.1080\/2162402X.2018.1509819","volume":"7","author":"JL Oyer","year":"2018","unstructured":"Oyer JL et al (2018) PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology 7:e1509819. https:\/\/doi.org\/10.1080\/2162402X.2018.1509819","journal-title":"Oncoimmunology"},{"key":"4333_CR32","unstructured":"Schafer JR, Valim V, Ciurea SO, Silla L, Sorathia K, et al. (2020) Early-phase clinical trials of adoptive transfer of hyperfunctional NK cells expanded ex vivo with IL-21 demonstrate functional, phenotypic, and haplotype-specific evidence of in vivo persistence, 25th European Hematology Association (EHA) (2020) Abstract #S284."},{"key":"4333_CR33","doi-asserted-by":"publisher","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman CJ et al (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7:e30264. https:\/\/doi.org\/10.1371\/journal.pone.0030264","journal-title":"PLoS ONE"},{"key":"4333_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cct.2017.04.006","volume":"58","author":"W Guo","year":"2017","unstructured":"Guo W et al (2017) A Bayesian interval dose-finding design addressingOckham\u2019s razor: mTPI-2. Contemp Clin Trials 58:23\u201333. https:\/\/doi.org\/10.1016\/j.cct.2017.04.006","journal-title":"Contemp Clin Trials"},{"key":"4333_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071777","author":"J Debska-Zielkowska","year":"2021","unstructured":"Debska-Zielkowska J et al (2021) KIR receptors as key regulators of NK cells activity in health and disease. Cells. https:\/\/doi.org\/10.3390\/cells10071777","journal-title":"Cells"},{"key":"4333_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1399-3046.2010.01447.x","volume":"15","author":"E Scquizzato","year":"2011","unstructured":"Scquizzato E et al (2011) KIR\/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation. Pediatr Transplant 15:198\u2013204. https:\/\/doi.org\/10.1111\/j.1399-3046.2010.01447.x","journal-title":"Pediatr Transplant"},{"key":"4333_CR37","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/cmi.2013.10","volume":"10","author":"M Cheng","year":"2013","unstructured":"Cheng M et al (2013) NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 10:230\u2013252. https:\/\/doi.org\/10.1038\/cmi.2013.10","journal-title":"Cell Mol Immunol"},{"key":"4333_CR38","doi-asserted-by":"publisher","first-page":"205796","DOI":"10.1155\/2014\/205796","volume":"2014","author":"R Romee","year":"2014","unstructured":"Romee R, Leong JW, Fehniger TA (2014) Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014:205796. https:\/\/doi.org\/10.1155\/2014\/205796","journal-title":"Scientifica (Cairo)"},{"key":"4333_CR39","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/JCO.2018.36.15_suppl.7008","volume":"36","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO et al (2018) Initial results of two phase I trials delivering mbIL-21 ex vivo expanded haploidentical NK cells after fludarabine\/cytarabine for patients with relapsed\/refractory myeloid leukemias. J Clin Oncol 36:7008\u20137008. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.7008","journal-title":"J Clin Oncol"},{"key":"4333_CR40","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2020.38.15_suppl.3025","volume":"38","author":"L Silla","year":"2020","unstructured":"Silla L et al (2020) CD56bright\/CD16bright NK-cell adoptive immunotherapy in patients with concurrent CNS disease and relapsed or refractory (R\/R) AML. J Clin Oncol 38:3025\u20133025. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.3025","journal-title":"J Clin Oncol"},{"key":"4333_CR41","doi-asserted-by":"publisher","first-page":"S227","DOI":"10.1016\/j.jtct.2023.12.296","volume":"30","author":"S Vasu","year":"2024","unstructured":"Vasu S et al (2024) SAR445419 off-the-shelf natural killer cells are safe and show efficacy signal in relapsed\/refractory acute myeloid leukemia. Transplant Cell Ther 30:S227\u2013S228. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.296","journal-title":"Transplant Cell Ther"},{"key":"4333_CR42","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE et al (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28:955\u2013959. https:\/\/doi.org\/10.1200\/JCO.2009.24.4590","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04333-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04333-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04333-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:58:06Z","timestamp":1775869086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04333-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4333"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04333-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the international ethics guidelines, including the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines for Good Clinical Practice (GCP), as well as all applicable laws, rules, and regulations. The study was approved by the Institutional Review Board at each site, and written informed consent was obtained from all study participants prior to their enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Marina Konopleva reports receiving consultancy fees from AbbVie, Forty Seven, Precision BioSciences, Gilead Sciences, Genentech, Janssen, Sanofi, MEI Pharma, Daiichi Sankyo Pharmaceutical, AstraZeneca Co., and Menarini; research funding from AbbVie, Allogene Therapeutics, Cellectis, Forty Seven, Gilead Sciences, Genentech, Sanofi, MEI Pharma, Rafael Pharmaceuticals, Daiichi Sankyo Pharmaceutical, AstraZeneca Co., Menarini, and Precision BioSciences; and holds shares\/stocks in Reata Pharmaceuticals. Ioannis Mantzaris reports having received honoraria from Kite Pharma. Reports participation in advisory board for Syndax. Abhishek Maiti reports receiving research funding from Celgene, Lin BioScience. Krishna Gundabolu reports receiving consultancy fees from Bristol-Myers Squibb, CTI BioPharma Corp, Blueprint Medicines, Sanofi Aventis GmbH, Spark Therapeutics. Reports participation advisory bords for Incyte and SOBI. Vijaya Raj Bhatt reports participating in the Safety Monitoring Committee for Protagonist, serving as a member of the National Comprehensive Cancer Network Acute Myeloid Leukemia Panel, as an associate editor for the journal Current Problems in Cancer, and as a contributor for BMJ Best Practice and receiving consulting fees from Jazz, research funding (institutional) from Cynata Therapeutics, MEI Pharma, Actinium Pharmaceutical, Sanofi U.S. Services, AbbVie, Pfizer, Incyte, Jazz, and National Marrow Donor Program, and drug support (institutional) from Chimerix for a trial. Naval Daver reports receiving consultancy fees from Bristol-Myers Squibb, Daiichi, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Jazz, Syndax, Sumitomo, Kura, AROG, Servier, Shattuck labs, Sanofi, Arcellx, Caribou, Debiopharm, Aptos, Astra-Zeneca, StemLine, VincerX; research funding from Hanmi, Trovagene, FATE, Novimmune, Glycomimetics, BMS, Astellas, Daiichi, Abbvie, Immunogen, Shattuck labs, Sanofi, Arcellx, Caribou, Debiopharm, Aptos, Astra-Zeneca, StemLine, VincerX, Nerviano, FATE therapeutics, Sumitomo, Kura Jolie Schafer, Kyle Jensen, Rao Saleem, Yi Li, Agata Drewniak, Pierre Bay, Winston Huh, Ozlem Yildirim, and Sarah Cooley are employee of Sanofi and may hold stocks and\/or stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}